Ipsen - October 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen reported outstanding sales growth of 24.6% at constant exchange rates in the first nine months of 2026, with its core portfolio achieving 24.2% growth. The company further upgraded its full-year 2026 financial guidance. Additionally, late-breaking data from the ELSPIRE study showed that IQIRVO® achieved ALP normalization in more than 85% of patients with primary biliary cholangitis (PBC), results to be presented at The Liver Meeting® 2026.